Long-term survival in patients with human immunodeficiency virus-associated small non-cleaved cell lymphoma: The role for short course intensive chemotherapy

Hematological Oncology

Volumn 21, Issue 3, 2003, Pages 131-140

  Astrow, Alan B ^a,c   Tarabay, Grace ^a   Salerno, Vincent E ^a   Cook, William A ^a   Lin, Robert ^a   Lascher, Steven ^a   Li, Zujun ^a   Mazumder, Amitabha ^a   Halperin, Ira ^a   Cho, John ^a   Jaffar, Zulfaq Quar ^a   McLaughlin, Marilyn ^a   Blum, Ronald H ^b   Kempin, Sanford J ^a  

^a Section of Allergy Immunology   (United States)

^b BETH ISRAEL MEDICAL CENTER   (United States)

^c ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Burkitt's lymphoma; HIV associated lymphoma; Small non cleaved lymphoma

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADULT; BLOOD TOXICITY; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; LYMPHOMA; MALE; MORTALITY; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SEPSIS; SHORT COURSE THERAPY; SMALL NON CLEAVED CELL LYMPHOMA; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BURKITT LYMPHOMA; COHORT STUDIES; FEMALE; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, SMALL NONCLEAVED-CELL; MALE; MIDDLE AGED; REGISTRIES; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 0142183698     PISSN: 02780232     EISSN: None     Source Type: Journal    
DOI: 10.1002/hon.715     Document Type: Review

References (35)

1. Ziegler JL, Miner RC, Rosenbaum E, et al. Outbreak of Burkitt's-like lymphoma in homosexual men. Lancet 1982; 2: 631-633.
2. Carbone A, Gloghini A, Gaidano G, et al. AIDS-related Burkitt's lymphoma: morphologic and immunophenotypic study of biopsy specimens. Am J Clin Pathol 1995; 103: 561-567.
3. Davi F, Delecluse HJ, Guiet P, et al. Burkitt-like lymphomas in AIDS patients: characterization within a series of 103 Human Immunodeficiency Virus-associated Non-Hodgkin's lymphomas. J Clin Oncol 1998; 16: 3788-3795.
4. Zeigler LD, Beckstead JA, Volberding PA, et al. Non-Hodgkin's lymphoma in 90 homosexual men: relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome. N Engl J Med 1984; 311: 565-570.
5. Lowenthal DA, Straus DJ, Cambell SW, et al. AIDS-related lymphoid neoplasia, the Memorial Hospital experience. Cancer 1988; 61: 2325-2337.
6. Knowles DM, Chamulak GA, Subar M, et al. Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS): The New York University Medical Center experience with 105 patients (1981-1986). Ann Int Med 1988; 108: 744-753.
7. Levine AM. Acquired immunodeficiency syndrome-related lymphoma (Review). Blood 1992; 80: 8-20.
8. Gill PS, Levine AM, Krailo M, et al. AIDS-related malignant lymphoma: results of prospective treatment trials. J Clin Oncol 1987; 5: 322-328.
9. Kaplan DJ, Abrams DI, Feigal E, et al. AIDS-associated non-Hodgkin's lymphoma in San Francisco. JAMA 1989; 261: 719-724.
10. Levine AM, Wernz JC, Kaplan L, et al. Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma: a prospective multi-institutional trial. JAMA 1991; 266: 84-88.
11. Kaplan LD, Strauss DJ, Testa MA, et al. Low-dose compared to standard dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. N Engl J Med 1997; 336: 1641-1648.
12. Strauss DJ. Treatment of Burkitt's lymphoma in HIV-positive patients. Biomed Pharm 1996; 50: 447-450.
13. McMaster ML, Greer JP, Greco FA, et al. Effective treatment of small noncleaved cell lymphoma with high-intensity, brief duration chemotherapy. J Clin Oncol 1991; 9: 941-946.
14. Sparano JA, Wiernik PH, Strack M, Leaf A, Becker N, Valentine ES. Infusional cyclophosphamide, doxorubicin and etoposide in human immunodeficiency virus and human T-cell leukemia virus type I-related non-Hodgkin's lymphoma: a highly active regimen. Blood 1993; 81: 2810.
15. Rosenberg SA, Berard CW, Brown BW Jr, et al. National Cancer Institute sponsored study of classification of non-Hodgkin's lymphoma. Summary and description of a Working Formulation for clinical usage. Cancer 1982; 42: 2112-2135.
16. Carbone PP, Kaplan HS, Musshaft K, et al. Report of the Committee on Hodgkin's Disease Staging. Cancer Res 1971; 31: 1860.
17. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
18. Kaplan LD, Kahn JO, Crowe JO, et al. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial. J Clin Oncol 1991; 9: 929-940.
19. Meadows A, Sposto R, Jenkins R, et al. Similar efficacy of 6 and 18 months of therapy with four drugs (COMP) for localized non-Hodgkin's lymphoma of children: a report from the Children's Cancer Study Group. J Clin Oncol 1989; 7: 92.
20. Longo DL, Devita VT Jr, Jubbard SM, et al. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J Clin Oncol 1991; 9: 25-38.
21. Cox DR. Regression models and life tables (with discussion). J R Stat Soc Ser B 1987; 34: 187-220.
22. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1965; 53: 1457-1481.
23. Navarro JT, Ribera JM, Oriol A, et al. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. Br J Hematol 2001; 112: 909-915.
24. Vaccher E, Spina M, di Gennaro G, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin's lymphoma. Cancer 2001; 91: 155-163.
25. Ratner L, Lee J, Tang S, et al. Chemotherapy for Human Immunodeficiency Virus-associated Non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001; 19: 2171-2178.
26. Carbone A, Canzonieri V, Gloghini A, et al. Burkitt's lymphoma: historical background and recent insights into classification and pathogenesis. Ann Otol Rhinol Laryngol 2000; 109: 693-702.
27. Bishop PC, Rao VK, Wilson WH. Burkitt's lymphoma: molecular pathogenesis and treatment. Cancer Invest 2000; 18: 574-583.
28. Soussain C, Patte C, Ostronoff M, et al. Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 1995; 85: 664-674.
29. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996; 14: 925-934.
30. Lee EJ, Petroni GR, Schiffer CA, et al. Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 Acute Lymphocytic Leukemia: results of Cancer and Leukemia Group B Study 9251. J Clin Oncol 2001; 19: 4014-4022.
31. Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 2002; 13: 1264-1274.
32. Longo DL, Duffey PL, Jaffe ES, et al. Diffuse small non-cleaved cell, non-Burkitt's lymphoma in adults: a high grade lymphoma responsive to ProMACE-based combination chemotherapy. J Clin Oncol 1994; 12: 2153-2159.
33. Norin T, Clifford P, Einhorn J, et al. Conventional and superfractionated radiation therapy in Burkitt's lymphoma. Acta Radiol 1971; 10: 545-557.
34. Link MP, Shuster JJ, Donaldson SS, et al. Treatment of children and young adults with early-stage Non-Hodgkin's lymphoma. N Engl J Med 1997; 337: 1259-1266.
35. Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 2002; 94: 1492-1499.